Failed in phase 3
Epoetin alfa: protect nerve tissue in optic neuritis
optic neuritis · Axonal protection / ion channels / excitotoxicity
Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 108
How the verdict was reached
Not supported in phase 3
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| TONE | Phase 3 | 108 | 2014 | Missed its main goal Mean pRNFL atrophy was 15·93 μm (SD 14·91) in the erythropoietin group and 14·65 μm (15·60) in the placebo group (adjusted mean treatment difference 1·02 μm; 95% CI -5·51 to 7·55; p=0·76). Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Results pending to Failed in phase 3
- Oct 2026First listed as Results pending
Related hypotheses
Assembled by software from public sources.